PKI News and Press, PerkinElmer Inc. From 04/21/21

Solid biopharma demand, rising diagnostic trends, and the economic recovery will support a ‘healthy’ Q1 revenue growth argues UBS analyst Dan Brennan and the team in a Q1 2021 preview written on the sector of life sciences & diagnostic tools.The firm picks IQVIA Holdings ([[...

No matter what industry we are talking about, political decisions, and policy changes can affect the price of the stocks in that industry, and Perkinelmer (NYSE: PKI) is not an exception.  PKI like every other company, it will experience ebbs and flows based on this type of news to...

Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 9...

The FDA has issued an emergency use authorization (EUA) for the PerkinElmer (PKI) SARS-CoV-2 RT-qPCR Reagent Kit.The kit is used with nasal swab test performed by healthcare providers as well as at-home tests.PerkinElmer shares are up 0.8% to $33.69 in afternoon trading. For furth...

Investors seem to be concerned about the revenue and margin pressures that Thermo Fisher will face as pandemic testing demand fades, but the impact isn't likely to be that bad. Bioproduction still offers significant long-term growth, as do areas of instrumentation like cytology, and t...

Trading Perkinelmer (NYSE: PKI) or any other stock for that matter requires a degree of disciple that not every investor has.  Even those that have discipline often fail to adhere to those disciplines sometimes, and this can cause problems, but hopefully the guides below will help ...

PerkinElmer has seen a huge increase in the demand for its products and services as a result of the pandemic. Earnings and revenue have increased dramatically in recent quarters and that growth is expected to continue when first quarter results come out. Sentiment toward the stock...

PerkinElmer ([[PKI]] -0.6%) company Horizon Discovery announces that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi).The new reagents include the first-ever commercially a...

CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to in...

When we read the charts for Perkinelmer (NYSE: PKI) we are able to reach conclusion that are not otherwise discernable.  We can see where buy signals exist, where sell signals exist, and where risk controls should be implemented.  These are what create trading plans.  The...